Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.65 AUD | +2.31% | -2.78% | -40.68% |
May. 15 | BMO Capital Adjusts Price Target on Arcadium Lithium to $5.50 From $6, Maintains Market Perform Rating | MT |
May. 10 | Arcadium Lithium Applies to Cease to be a Reporting Issuer in Canada | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's enterprise value to sales, at 4.21 times its current sales, is high.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.68% | 4.76B | - | ||
+17.07% | 66.31B | A- | ||
-0.29% | 48.46B | A- | ||
+21.61% | 43.27B | B+ | ||
+26.72% | 27.41B | A- | ||
+9.25% | 19.26B | C+ | ||
-2.14% | 16.61B | B+ | ||
+9.75% | 16.58B | B+ | ||
-15.01% | 14.41B | C+ | ||
-30.22% | 14.02B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALTM Stock
- LTM Stock
- Ratings Arcadium Lithium plc